# Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance

> **NCT06634667** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Hunan Province Tumor Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** third-generation EGFR-TKI combined with anlotinib

## Key facts

- **NCT ID:** NCT06634667
- **Lead sponsor:** Hunan Province Tumor Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-11-30
- **Primary completion:** 2026-08-31
- **Final completion:** 2027-04-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06634667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06634667, "Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06634667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*